Clinical caracteristics, management and pronostic evolution of patients admitted within six hours of symptom onset with st-segment elevation acute myocardial infarction complicated by cardiogenic shock : twenty year monocentric experience
##plugins.themes.academic_pro.article.main##
Abstract
Background : Cardiogenic shock is one of the most serious complications of the acute myocardial infarction. Advances in interventional cardiology and early reperfusion strategy improved its management.
Aim: Analysis of the clinical characteristics, management and prognostic evolution of patients admitted within 6 hours onset with ST-segment elevation acute myocardial infarction complicated by cardiogenic shock.
Methods: Follow-up study based on 2200 consecutive patients admitted with STEMI within 6 hours of symptom onset from 1988 to 2008. Among them 114 matched the criteria of cardiogenic shock. These were divided in two groups, according to the period: group 1 (N=57, among the first 1100 STEMI from 1988 to 1998) and group 2 (N=57, among the following 1100 STEMI from 1999 to 2008).
Results: This trial shows a similar rate of cardiogenic shock in STEMI (5%) in both 1100 patients groups. There is no overall change in patient’s clinical characteristics, but improvements in earlier management, prehospital fibrinolysis and ventricular fibrillation treatment have been detected. Primary percutaneous coronary intervention was the most common revascularisation strategy. The proportion of patients achieving acute TIMI-3 flow in the infarct related artery increased (61% vs 80%, p= 0.11) but the mortality was still high (74% vs 63%, p= 0.22).
Conclusion: The clinical characteristics of cardiogenic shock remain unchanged; its management is more successful with more often early reperfusion. The decline of mortality is unfortunately not significant. More aggressive treatment should probably be considered to improve outcomes.
Aim: Analysis of the clinical characteristics, management and prognostic evolution of patients admitted within 6 hours onset with ST-segment elevation acute myocardial infarction complicated by cardiogenic shock.
Methods: Follow-up study based on 2200 consecutive patients admitted with STEMI within 6 hours of symptom onset from 1988 to 2008. Among them 114 matched the criteria of cardiogenic shock. These were divided in two groups, according to the period: group 1 (N=57, among the first 1100 STEMI from 1988 to 1998) and group 2 (N=57, among the following 1100 STEMI from 1999 to 2008).
Results: This trial shows a similar rate of cardiogenic shock in STEMI (5%) in both 1100 patients groups. There is no overall change in patient’s clinical characteristics, but improvements in earlier management, prehospital fibrinolysis and ventricular fibrillation treatment have been detected. Primary percutaneous coronary intervention was the most common revascularisation strategy. The proportion of patients achieving acute TIMI-3 flow in the infarct related artery increased (61% vs 80%, p= 0.11) but the mortality was still high (74% vs 63%, p= 0.22).
Conclusion: The clinical characteristics of cardiogenic shock remain unchanged; its management is more successful with more often early reperfusion. The decline of mortality is unfortunately not significant. More aggressive treatment should probably be considered to improve outcomes.
Keywords:
Acute myocardial infarction, cardiogenic shock, percutaneous coronary intervention, Fibrinolysis##plugins.themes.academic_pro.article.details##
References
- Goldberg RJ, Samad NA, Yarzebski J, Gurwitz J, Bigelow C, Gore JM. Temporal trends (1975-1997) in the incidence and hospital death rates of cardiogenic shock complicating acute myocardial infarction (Worcester Heart Attack Study) N Engl J Med. 1999;340:1162-68.
- Holmes DR Jr, Bates ER, Kleiman NS et al. Contemporary reperfusion therapy for cardiogenic shock: the GUSTO-I trial experience. The GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. J Am Coll Cardiol 1995;26: 668-74.
- Barron HV, Every NR, Parsons LS, et al. The use of intra-aortic balloon counterpulsation in patients with cardiogenic shock complicating acute myocardial infarction: data from the National Registry of Myocardial Infarction 2. Am Heart J 2001;141:933-39.
- Hochman JS, Buller CE, Sleeper LA, et al. Cardiogenic shock complicating acute myocardial infarction: etiologies, management and outcome: A report from the SHOCK trial registry. J Am Coll Cardiol 2000;36:1063-70.
- Juliard JM, Golmard JL, Ducrocq G et al. Universal reperfusion therapy can be implemented: lessons from 20 years of management of patients admitted within 6 hours of symptom onset with STsegment elevation acute myocardial infarction. Arch Cardiovasc Dis 2009; 102 : 259—67.
- The TRIUMPH Investigators. Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock. The TRIUMPH Randomized Controlled Trial. JAMA 2007;297:1657-66.
- Babaev A, Frederick PD, Pasta DJ et al. Trends in management and outcomes of patients with acute myocardial infarction complicated by cardiogenic shock. JAMA 2005;294:448-54.
- Klein LW, Shaw RE, Krone RJ, et al . Mortality after emergent percutaneous coronary intervention in cardiogenic shock secondary to acute myocardial infarction and usefulness of a mortality predication model. Am J Cardiol 2005; 96: 35-41.
- Maggioni AP, Maseri A, Fresco C, et al. The investigators of the Gruppo Italianoper lo Studio della Sopravvivenza nell Infarto Miocardico (GISSI-2). Age-related increase in mortality among patients with first myocardial infarction treated with thrombolysis. N Engl J Med 1993; 329: 1442-8.
- Ana Garcia-Alvarez, Dabit Arzamendi, Pablo Loma-Osorio, et al. Early Risk Stratification of Patients With Cardiogenic Shock Complicating Acute Myocardial Infarction Who Undergo Percutaneous Coronary Intervention. Am J Cardiol 2009;103: 1073- 77
- Webb JG, Lowe AM, Sanborn TA et al. PCI for cardiogenic shock in the SHOCK trial. J Am Coll Cardiol 2003; 42: 1380-6
- Van de Werf F, Bax J, Betriu A, et al. Management of acute myocardial infarction in patients presenting with persistent STsegment elevation: the Task Force on the management of STsegment elevation acute myocardial infarction of the European Society of Cardiology. Eur Heart J 2008;29:2909-45.
- Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction—executive summary. Circulation 2004;110:588-636.
- KD. Sjauw, AE. Engstrom, MM. Vis, et al. A systematic review and meta-analysis of intra-aortic balloon pump therapy in ST-elevation myocardial infarction: should we change the guidelines. Eur Heart J 2009: 30, 459-68
- Melchior S, Sibbing D, Bauer I, et al. A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction. J Am Coll cardiol 2008; 52: 1584-8
- Steg PG, Bonnefoy E, Chabaud S, et al. Impact of time to treatment on mortality after prehospital fibrinolysis or primary angioplasty: data from the CAPTIM randomized clinical trial. Circulation 2003;108:2851-56
- Kalla K, Christ G, Karnik R, et al. Implementation of guidelines improves the standard of care: the Viennese registry on reperfusion strategies in ST-elevation myocardial infarction (Vienna STEMI registry). Circulation 2006;113:2398-2405.